Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial
Open Access
- 23 April 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (4) , e0196239
Abstract
Weekends off antiretroviral therapy (ART) may help engage HIV-1-infected young people facing lifelong treatment. BREATHER showed short cycle therapy (SCT; 5 days on, 2 days off ART) was non-inferior to continuous therapy (CT) over 48 weeks. Planned follow-up was extended to 144 weeks, maintaining original randomisation. BREATHER was an open-label, non-inferiority trial. Participants aged 8-24yrs with virological suppression on efavirenz-based first-line ART were randomised 1:1, stratified by age and African/non-African sites, to remain on CT or change to SCT. The Kaplan-Meier method was used to estimate the proportion of participants with viral rebound (confirmed VL≥50 copies/mL) under intent-to-treat at 48 weeks (primary outcome), and in extended follow-up at 96, 144, and 192 weeks. SCT participants returned to CT following viral rebound, 3 VL blips or discontinuation of efavirenz. Of 199 participants (99 SCT, 100 CT), 97 per arm consented to extended follow-up. Median follow-up was 185.3 weeks (IQR 160.9–216.1). 69 (70%) SCT participants remained on SCT at last follow-up. 105 (53%) were male, baseline median age 14 years (IQR 12–18), median CD4 count 735 cells/μL (IQR 576–968). 16 SCT and 16 CT participants had confirmed VL≥50 copies/mL by the end of extended follow-up (HR 1.00, 95% CI 0.50–2.00). Estimated difference in percentage with viral rebound (SCT minus CT) by week 144 was 1.9% (90% CI -6.6–10.4; p = 0.72) and was similar in a per-protocol analysis. There were no significant differences between arms in proportions of participants with grade 3/4 adverse events (18 SCT vs 16 CT participants; p = 0.71) or ART-related adverse events (10 vs 12; p = 0.82). 20 versus 8 serious adverse events (SAEs) were reported in 16 SCT versus 4 CT participants, respectively (p = 0.005 comparing proportions between groups; incidence rate ratio 2.49, 95%CI 0.71–8.66, p = 0.15). 75% of SAEs (15 SCT, 6 CT) were hospitalisations for a wide range of conditions. 3 SCT and 6 CT participants switched to second-line ART following viral failure (p = 0.50). Sustainable non-inferiority of virological suppression in young people was shown for SCT versus CT over median 3.6 years. Standard-dose efavirenz-based SCT is a viable option for virologically suppressed HIV-1 infected young people on first-line ART with 3-monthly VL monitoring. EudraCT 2009-012947-40 ISRCTN 97755073 ClinicalTrials.gov NCT01641016Keywords
Funding Information
- Medical Research Council
- UK National Institute for Health Research Health Technology Assessment (08/53/25;11/136/108)
- European Commission (EuroCoord FP7/2007/2015)
- The Paediatric European Network for Treatment of AIDS (PENTA) Foundation
- French National Institute of Health and Medical Research. French Aids Research Agency (INSERM-ANRS)
This publication has 16 references indexed in Scilit:
- Interventions to improve treatment, retention and survival outcomes for adolescents with perinatal HIV-1 transitioning to adult careCurrent Opinion in HIV and AIDS, 2016
- Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysisThe Lancet HIV, 2016
- Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsPLOS ONE, 2016
- Antiretroviral Therapy Enrollment Characteristics and Outcomes Among HIV-Infected Adolescents and Young Adults Compared with Older Adults - Seven African Countries, 2004-20132014
- Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challengesThe Lancet Infectious Diseases, 2014
- ‘Children will always be children’: Exploring perceptions and experiences of HIV-positive children who may not take their treatment and why they may not tellAfrican Journal of AIDS Research, 2014
- High attrition before and after ART initiation among youth (15–24 years of age) enrolled in HIV careAIDS, 2014
- A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in UgandaPLOS ONE, 2010
- Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- O214 The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapyJournal of the International AIDS Society, 2008